ACADIA Pharmaceuticals Inc
NASDAQ:ACAD

Watchlist Manager
ACADIA Pharmaceuticals Inc Logo
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
Watchlist
Price: 21.55 USD -1.37% Market Closed
Market Cap: 3.6B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one ACAD stock under the Base Case scenario is 23.16 USD. Compared to the current market price of 21.55 USD, ACADIA Pharmaceuticals Inc is Undervalued by 7%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ACAD Relative Value
Base Case
23.16 USD
Undervaluation 7%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3.8
P/S
P/S
Price to Sales
3.8
vs History
76
vs Industry
71
Median 3Y
5
Median 5Y
6
Industry
6.8
Forward
3.3
More Details
15.9
P/E
P/E
Price to Earnings
15.9
vs History
9
vs Industry
10
Median 3Y
-13.3
Median 5Y
-17.2
Industry
21.9
Forward
36.1
More Details
22.8
P/OCF
P/OCF
Price to OCF
22.8
vs History
14
vs Industry
10
Median 3Y
-17.9
Median 5Y
-24.3
Industry
19.5
More Details
22.9
P/FCFE
P/FCFE
Price to FCFE
22.9
vs History
9
vs Industry
9
Median 3Y
-21.1
Median 5Y
-25.8
Industry
23.4
More Details
4.9
P/B
P/B
Price to Book Value
4.9
vs History
84
vs Industry
24
Median 3Y
6.2
Median 5Y
7
Industry
2.4
More Details
2.5
EV/S
EV/S
Enterprise Value to Sales
2.5
vs History
80
vs Industry
69
Median 3Y
4.2
Median 5Y
5.3
Industry
7.2
Forward
2.2
More Details
2.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.7
vs History
80
vs Industry
70
Median 3Y
4.3
Median 5Y
5.6
Industry
9.1
More Details
24
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
24
vs History
9
vs Industry
9
Median 3Y
-9.8
Median 5Y
-13.2
Industry
3.9
Forward
18.4
More Details
28.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
28.5
vs History
4
vs Industry
7
Median 3Y
-11.1
Median 5Y
-14.3
Industry
3.8
Forward
25.7
More Details
15.2
EV/OCF
EV/OCF
Enterprise Value to OCF
15.2
vs History
14
vs Industry
13
Median 3Y
-14.6
Median 5Y
-20.4
Industry
4.4
More Details
15.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
15.3
vs History
9
vs Industry
10
Median 3Y
-17.8
Median 5Y
-22.7
Industry
3.5
More Details
Negative
EV/IC
EV/IC
Enterprise Value to IC
N/A
vs History
vs Industry
27
Median 3Y
12
Median 5Y
14.2
Industry
4.4
More Details

Multiples Across Competitors

ACAD Competitors Multiples
ACADIA Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
3.6B USD 3.8 15.9 24 28.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 35 151 035.5 -167 067.7 -202 873.4 -200 558.4
US
Abbvie Inc
NYSE:ABBV
322.4B USD 5.6 77.6 14.9 22
US
Amgen Inc
NASDAQ:AMGN
146.2B USD 4.3 24.6 13.5 22.2
US
Gilead Sciences Inc
NASDAQ:GILD
133.3B USD 4.6 22.3 9.7 13.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
111.3B USD 10 -112.6 23.9 25
US
Epizyme Inc
F:EPE
94.1B EUR 2 004.2 -511.4 -556.9 -542
AU
CSL Ltd
ASX:CSL
119.4B AUD 5 27.9 17.2 21.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
64.6B USD 4.6 14.4 12.9 14.5
US
Seagen Inc
F:SGT
39.3B EUR 19.3 -59.2 -63.8 -57.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
37.7B USD 16.1 -139.9 -625 -313.2
P/E Multiple
Earnings Growth PEG
US
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
Average P/E: 30.4
15.9
1%
15.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -167 067.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
77.6
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.6
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
22.3
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -112.6 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -511.4 N/A N/A
AU
CSL Ltd
ASX:CSL
27.9
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.4
7%
2.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -139.9 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
Average EV/EBITDA: 16.6
24
53%
0.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -202 873.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.9
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
13.5
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.7
7%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
18%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -556.9 N/A N/A
AU
CSL Ltd
ASX:CSL
17.2
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.9
14%
0.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -63.8 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -625 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
Average EV/EBIT: 21
28.5
45%
0.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -200 558.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
22.2
31%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.4
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -542 N/A N/A
AU
CSL Ltd
ASX:CSL
21.5
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.5
13%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.5 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -313.2 N/A N/A

See Also

Summary
ACAD intrinsic value, competitors valuation, and company profile.
DCF Valuation
ACAD stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ACAD stock valuation using valuation multiples.
Wall Street Estimates
ACAD price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ACAD stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 256,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.